A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes

Key facts

Study ID

NCT00374907

Run by

AstraZeneca

People needed

156

Starts

2006-09-01

Expected to finish

2009-12-01

Last updated by the study team

2015-05-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes mellitus
• Drug naive
• Hemoglobin A1c (HbA1c) ≥6.0% and ≤8.0%
• Fasting C-peptide ≥1.0 ng/mL
• Body mass index ≤40 kg/m²

You may not qualify if…

• Recent cardiac or cerebrovascular event
• Elevated serum creatinine

Where it is running

• Va San Diego Healthcare System — San Diego, California, United States
• Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States
• Diabetes & Glandular Disease Research Assoc,, Inc. — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.